Kapitza C, Nosek L, Schmider W, et al. - Given that SAR341402 Mix 70/30 (SAR_Asp‐Mix) is a premixed formulation with 70% protamine‐crystallized insulin aspart and 30% soluble insulin aspart, researchers conducted this randomized, double‐blind, crossover trial to compare pharmacokinetic exposure of SAR_Asp‐Mix to US‐ and EU‐approved versions of insulin aspart Mix 70/30 (NovoLog Mix 70/30 [NN‐Mix‐US] / NovoMix 30 [NN‐Mix‐EU]) and SAR341402 insulin aspart solution (SAR‐Asp) in patients with type 1 diabetes. For this analysis, 52 patients received a single subcutaneous 0.3 U/kg dose of each treatment and underwent a euglycemic clamp procedure lasting for a maximum of 24 h after dosing. According to findings, SAR_Asp‐Mix showed comparable pharmacokinetic exposure to commercially available insulin aspart Mix 70/30 formulations, and a distinct exposure profile compared with SAR‐Asp.